Fast Track is a process designed to expedite FDA review and get important new drugs to the patient earlier.
News & Stories
Lupus is the feature of a new publication by the largest non-profit alliance committed to making medical research a national priority.
This week, LFA-supported researchers will share results of a study that could help expedite the delivery of new and safer therapies to people with lupus.
30 researchers funded by the LFA are presenting this week at the annual scientific meeting of the American College of Rheumatology. #ACR16 is among the world’s largest gatherings where results of medical research studies in the area of rheumatology are presented for critical peer evaluation.
We're honored to announce the winners of this year's Evelyn V. Hess Award and Mary Betty Stevens Young Investigator Prize.
Aurinia Pharmaceuticals announced its plans for a single Phase III clinical trial for voclosporin in the treatment of lupus nephritis.
Dr. Furie explains the clinical research process to help those living with lupus make an informed decision about participation.
Trial results offer hope of a more effective and tolerable treatment option to manage lupus-related kidney disease.
One of our key goals is to ensure people with lupus have access to the care and treatments they need. Recently, access to a few vital treatments has been challenging to obtain, specifically access to quinacrine, hydroxychloroquine, and Benlysta®.
Like "love languages", for those with chronic disease, a sense of well-being is more about the match between the kind of support we want and the kind we receive.
The year-long initiative to make research on lupus treatments more inclusive and effective formally began on July 1.
Dr. Susan Boackle discusses the medications used to treat lupus and research underway to identify markers that can predict who might develop lupus or go into a disease flare.
In some diseases, like lupus, sex-based differences may be the key to unlocking the mysteries and getting closer to treatments and cures.
Dr. Marshak-Rothstein will use the $200,000 award to advance her groundbreaking research into cutaneous lupus and autoimmunity.
Participating in research can be a rewarding experience, and is essential to improve the quality of life of people with lupus.
The provision was approved by the U.S. House of Representatives' Appropriations Committee.
The study will examine the medical impact of mindfulness interventions for lupus patients.
Today, the Lupus Foundation of America announced results of a first-of-its-kind study that could expedite the delivery of new and safer therapies to people with lupus.
Lupus Organizations Continue Collaborating to Spark Innovation and Scientific Advances in Lupus Research
Through a rigorous peer-review process, the Foundation will fund the most promising research focused on improving the quality of life for people with lupus.
A new study points to specific changes companies can make in clinical trials so that, in the future, clearer data can lead us closer to a cure.
The research plan identifies and examines opportunities to increase scientific understanding of lupus, which will ultimately lead to safer and more effective treatments and, eventually, curative strategies
Congress voted to pass the Consolidated Appropriations Act (H.R. 2029) that will fund the federal government for 2016. Thanks to the leadership of the Lupus Foundation of America and our vast network of dedicated lupus activists, the bill provides significant funding increases and vital support for lupus research and education programs.
Last night, Congress unveiled its Consolidated Appropriations Act (H.R. 2029) that will fund the federal government for 2016. Thanks to the leadership of the Lupus Foundation of America and our vast network of dedicated lupus activists, the bill provides significant funding increases and vital support for lupus research and education programs. As the bill makes its way through Congress, we will keep you updated you on its progress.
Dr. Niewold's lab is mapping the genetic factors that cause autoimmune diseases and how variations can lead to disease onset.
Dr. Kaplan describes her research to understand the role of inflammation in causing premature cardiovascular disease in lupus and the role of a specific white blood cell in causing lupus and its progression.
Anifrolumab significantly reduced disease activity as measured by several SLE composite endpoints and improved symptoms of lupus.
With the last day of the American College of Rheumatology Annual Meeting upon us, we’re ready to bring you updates on the latest findings in lupus research.
We’re back for day two of the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco.
10th Anniversary of the Evelyn V. Hess Award Celebrates Past Honorees
Our team is on the ground in San Francisco to bring you the latest in lupus research and live updates from the American College of Rheumatology's Annual Meeting.
Eight LFA-supported research studies presented during the American College of Rheumatology Annual Scientific Meeting
The Lupus Foundation of America research grants will support important studies on immune cells, pediatric lupus, stem cells, biomarkers, and environmental triggers of lupus.
A new analysis of data from a phase II clinical study of Edratide support the need for additional longer term studies in lupus.
Dr. Laura Plantinga of Emory University discusses data from a study of end-stage renal disease among newly diagnosed lupus patients.
To mark the first anniversary of Lupus Science and Medicine Harriet Vickers speaks to Dr. Ronald van Vollenhoven and Dr. Jill Buyon about notable published papers, publishing without an impact factor and what to expect from the journal in the coming year.
These research awards seek to develop the next generation of lupus scientific leaders by fostering an interest in lupus research careers.
Grant Project Aims to Improve Lupus Nephritis Treatment
Lupus Foundation of America Hosts Awards Dinner & 21st Century Cures Discussion
Jasvinder Singh, M.D., a prominent researcher in rheumatic disease, has been awarded a $1.5 million, three year grant from the Patient-Centered Outcomes Research Institute for a decision aid to help doctors and their African-American and Hispanic lupus patients with kidney disease choose the best treatment for each individual patient.
This year, the Foundation’s National Research Program will fund priority areas in lupus research, including new grants in environmental triggers of lupus and health outcomes in pediatric lupus.
Lupus experts predict next years of progress
The request for nominations for the Lupus Insight Prize will open January 15, 2015 and will be awarded at the Federation of Clinical Immunology Societies (FOCIS) annual meeting in San Diego this June.
Working together with stakeholders, we take great pride in the following 2014 accomplishments and advancements in lupus research and awareness.
Dr. Jane Salmon reflects on the changing perspectives regarding lupus and pregnancy and her lifelong work to better understand the causes of pregnancy loss and organ damage in lupus.
Dr. Tsokos is conducting research to explore the molecular origin of the multiple immune cell abnormalities in lupus, and to identify novel biomarkers for diagnosis and therapeutic targets for treatment.
Dr. Eliza Chakravarty is conducting research to advance understanding of immunological changes of pregnancies in women with lupus to gain insight and improve outcomes.
Dr. Diane Kamen is investigating whether microbes in the gut are capable of contributing to the development of lupus in African Americans with a genetic predisposition for the disease.
The Lupus Nephritis Trials Network (LNTN) is a worldwide organization that brings researchers together with the shared goal of improving outcomes for patients with lupus nephritis.
Dr. Stacy P. Ardoin's research will help determine whether levels of microRNA in the urine can indicate lupus nephritis-related disease activity and damage in the kidneys of children with lupus.
The Lupus Foundation of America Corporate Advisory Council provides industry perspective helping identify and address barriers to lupus drug development.
Statement from Sandra C. Raymond, President and CEO of the Lupus Foundation of America
Dr. Laura Lewandowski is conducting a study that will help to better understand the burden of pediatric lupus and the role of race in lupus severity.
Sarah Stothers, Lupus Foundation of America Health Educator, reports back about findings from American College of Rheumatology's Annual Meeting in Boston last month. Read more.
During this season of gratitude, we are so thankful for caring and passionate supporters like you.
The annual American College of Rheumatology (ACR) Annual Scientific Meeting, a major event in the rheumatology community, is coming to an end today but our work doesn’t stop here.
We will be featuring Lupus Foundation of America initiatives and other Foundation-funded research today, as well as attending sessions on anti-phosopholipid syndrome and other sessions of interest to people living with lupus. Learn more!
This week, we are celebrating the first anniversary of the official launch announcement of Lupus Science & Medicine™ the first-ever international, Open Access medical journal dedicated to advancing knowledge in the diagnosis, treatment and management of lupus and related diseases.
Lupus Foundation of America presents prestigious career awards during American College of Rheumatology Annual Scientific Meeting
Today’s sessions will focus on pediatric lupus and biomarkers, including a Foundation-funded research program about pediatric lupus in South Africa. Learn more!
The annual American College of Rheumatology (ACR) Annual Scientific Meeting is taking place November 15-19 in Boston, MA. Learn more.
LFA-REAL is a two part system, based on a series of simple questions and observations, to determine a treatment’s impact on the patient’s health and daily life.
Foundation-funded research studies highlighted at premier rheumatology meeting in Boston.
Award is the largest amount allocated to lupus since 2006
Sandra C. Raymond, President & CEO of the Lupus Foundation of America, issued the following statement in response to Eli Lilly and Company’s announcement of the results of two Phase III clinical trials of tabalumab.
The Lupus Foundation of America congratulates and welcomes the first 11 new research groups that have been awarded grants as part of the Accelerating Medicines Partnership in Lupus and Rheumatoid Arthritis (AMP Lupus and RA) Network.
Increasing funding for lupus research is a top priority for the Lupus Foundation of America. We urge Congress to robustly fund the National Institutes of Health (NIH), the largest source of biomedical research (and lupus) funding in the country.
Leading Orgs Take to the Hill to Discuss Need to Accelerate New Medicines for Lupus & Other Diseases
Lupus Foundation of America and Rheumatology Research Foundation hold congressional briefing
Jennifer Mall, M.P.H. discusses her research project as part of her Gina Finzi Fellowship experience during the summer of 2014.
Dr. Gary Gilkeson discusses the role of adult stem cells in the immune system and how they can be used to manage lupus.
Study funded by the Foundation's National Lupus Research Program secures NIH planning grant to develop a multi-center trial of mesenchymal stem cells.
Flare rates among participants receiving a low dose of the b-cell blocker did not meet primary endpoint but were lower for individuals receiving a higher dose.
Treat-to-Target is a treatment approach that has been used successfully in other diseases, including rheumatoid arthritis and diabetes. An international group of lupus experts has developed a set of recommendations for using this principle in lupus.
An international group of lupus experts has developed a set of recommendations to implement the treat-to-target strategy for managing lupus.
Victoria P. Werth, M.D., member of the Lupus Foundation of America Medical-Scientific Advisory Council, talks about current research on new treatments for lupus that affects the skin.
Lupus Foundation of America announces its 2014 National Lupus Research Program Summer Fellowships and Career Development Awards
Epigenetics is a field of science that examines factors which influence whether genes are turned on or off when cells are replicated, which can influence whether a person might develop a specific disease, such as lupus.
Bruce Richardson, M.D., Ph.D., of the University of Michigan, was honored for his research findings that have made significant contributions to the field and have a high likelihood of generating further insights in understanding the disease.
Additional data from the CDC National Lupus Patient Registry project demonstrates that lupus is a widespread disease with a significant impact.
Dr. Richardson’s work has provided a strong foundation from which further advances in the understanding and treatment of lupus can be made.
The Lupus Foundation of America announced today that the Foundation is seeking grant applications to provide critical funding that will, for the first time, address an unmet need in pediatric lupus nephritis.
A new study published in Arthritis Care & Research offers a first time, in-depth look at educational and employment outcomes in adults with childhood-onset lupus and provides new insights into properly navigating the path from adolescence to adulthood.
Lupus Science & Medicine™ is launched to provide the latest lupus research and stimulate collaborative efforts to improving the lives of all people affected by lupus.
The stories of four people whose lives have been forever changed by lupus and the Foundation's efforts to improve the quality of life for everyone affected by lupus.
LFA-REAL will address major challenges in lupus treatment and disease management, and has the potential to greatly improve medical care and quality of life for people living with lupus.
Sandra C. Raymond, President and CEO of Lupus Foundation of America, was featured on BioCentury This Week to speak about lupus and the Accelerating Medicines Partnership (AMP). Watch now!
A bird’s eye view of lupus research from the Lupus Foundation of America’s Education and Research Department
Congress passed the Consolidated Appropriations Act of 2014. While this funding brings some good news in the fight against lupus, the Act only restores some of the money to the NIH that was previously cut through the automatic spending reductions (sequestration).
Study examines the effects of the antimalarial drug, hydroxycloroquine, on antiphospholipid antibodies that are responsible for pregnancy complications in women with lupus and antiphospholipid syndrome.
Information about burden of disease and quality of life will help guide policy, program and investment decisions to solve the cruel mystery of lupus.
This valuable tool will help doctors prevent atherosclerosis, a life-threatening complication of lupus.
The Lupus Foundation of America will partner with the Foundation for the National Institutes of Health (FNIH) to support a new $230 million, five-year initiative that will accelerate the ability to develop new medicines for lupus and other diverse and complex diseases.
New LIFELINE Grant Will Help Sustain Lupus Research That’s at the Brink of Breakthrough.
Lupus Foundation of America supported study finds combination therapy that includes hydroxychloroquine may be beneficial to pregnant patients with lupus and/or antiphospholipid syndrome.
The Lupus Foundation of America applauds Congress for enacting the Consolidated Appropriations Act of 2014, H.R. 3547 which provides funding for vital lupus research and education programs.
As 2013 comes to an end, Sandra C. Raymond, President and CEO, reflects on the advances Lupus Foundation of America has made over the years, and speaks about the key priorities for the future.
Our research, education and advocacy programs in 2013 contributed advances that are helping to solve the cruel mystery of lupus.
Lupus Insight Prize to be awarded to Outstanding Scientist
Learn strategies to cope with lupus, connect with others living with lupus, and attend our walk kick off. (seperate registration required)
Learn strategies to cope with lupus, connect with others living with lupus, and attend our Jacksonville walk kick off.
Please join us Orlando for your Walk to End Lupus Now Kick-Off Party! Come get to know us and connect with others who have been impacted by lupus.
Come and get to know our organization and connect with others in your community who have also been impacted by lupus.
Join us at Marlins Park as we walk to end lupus now at Florida's largest lupus walk!
Join us for our 2017 Palm Beach Walk to End Lupus Now at the Palm Beach Zoo!
Join us in Orlando to raise money for lupus research, increase awareness of lupus, and rally public support
Join us in Jacksonville to raise money for lupus research, increase awareness of lupus, and rally public support for the estimated 1.5 million Americans who suffer from its brutal impact.
We invite you to join us at Anthony's Coal Fired Pizza in Coral Gables for our Pizza with a Purpose Fundraiser! Bring along your friends and family to celebrate the upcoming Walk to End Lupus Now in Miami- Florida's largest lupus walk!
La Fundacion Americana de Lupus, Capitulo de Florida les invita a participar en la caminata mas grande de lupus de la Florida para recaudar fondos y levantar el conocimiento sobre lupus.
We invite you to join us at Chipotle for a night out for lupus! Bring along your friends and family to celebrate the upcoming Walk to End Lupus Now in Miami – Florida’s largest lupus walk!
This educational teleconference will address complications, medical evaluation and treatment as it relates to kidney involvement in lupus.
Please join us for our Living Well with Lupus Seminar in Orlando.
View upcoming support groups, educational programs, fundraising events, and more.
Thank you Palm Beach for coming out to Walk to End Lupus Now. You have until July 5 to turn in your donations and help us reach our goal.
Thank you Orlando for coming out to Walk to End Lupus Now. You have until June 21 to turn in your donations and help us reach our goal.
Thank you Jacksonville for coming out to Walk to End Lupus Now. You have until April 13 to turn in your donations and help us reach our goal.
Are you interested in starting a group in your area or becoming a co-facilitator of an exisiting group? If, so we invite you to attend our next facilitator training.
Thank you for Melbourne for coming out to Walk to End Lupus Now. You have until December 14 to turn in your donations and help us reach our goal.
Thank you for Miami for coming out to Walk to End Lupus Now. You have until November 30 to turn in your donations and help us reach our goal.
Join us for our third annual Southwest Florida Walk to end Lupus now in Naples. Lets rally together to create awareness of lupus while raising funds to fight this terrible disease.
NEW in 2015! The Walk to End Lupus Now is coming to Northern Florida in Jacksonville. Join us as we rally together to create awareness of lupus while raising funds to fight this terrible disease.
What you need to know to help with issues surrounding disability.
Patients, caregivers, and the medical community are invited to join us for a day devoted to those affected by lupus. The Annual NC Lupus Summit is the largest educational conference on lupus in the state and provides a variety of discussions led by physicians and other experts dedicated to solving the cruel mystery of lupus. This year's event will highlight aiming high to live a meaningful life.
An educational symposium brought to you by the Lupus Foundation of America, Inc.
Feel empowered to advocate for yourself on a social and political level to overcome healthcare barriers.